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Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
Background: Chronic obstructive pulmonary disease (COPD) is a common comorbidity in
patients with lung and head- and neck cancer. Patients with lung cancer who also suffer from
COPD have a worse prognosis than patients with lung cancer and no COPD. It has previously
been shown that diagnosis and treatment of concomitant COPD in patients with newly diag-
nosed lung- or head and neck cancer need optimization. In this randomized, controlled trial we
aimed to assess if intervention directed at improving treatment for COPD in these patients
improved health-related quality of life (QoL).
Methods: During 2014, we randomized 114 patients referred for oncological treatment at a large
university hospital in the Capital Region of Denmark, to either usual care or intervention regard-
ing concomitant COPD. The intervention consisted of two visits in an out-patient clinic estab-
lished at the oncological department and staffed with a pulmonary physician. At baseline, week
13 and week 25, all patients filled out the cancer- and COPD-specific QoL questionnaires CAT and
EORTC, respectively. The primary outcome was change in CAT-score between control- and
intervention group. The secondary outcome was change in EORTC.
Results: There was no change in CAT-score by week 13 or 25 between the groups. For the EORTC
there was a statistically significant improvement only in the fatigue domain at week 13 (p = 0.03),
but not at week 25. There was a trend towards less dyspnea in the intervention group at week 13,
measured by EORTC (p = 0.07). Mortality by week 25 was similar in both groups.
Conclusion: In this population of severely ill cancer patients, we did not find that this intervention,
focusing on inhaled COPD medication, for the management of COPD had any convincing positive
impact on the patients’ perceived quality of life compared with usual care. Further studies are needed.
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Introduction
Breathlessness, fatigue, and cough/sputum are the most
common symptoms in COPD [1,2,] and are also pre-
valent in lung cancer (LC) [3]. Patients with head- and
neck cancer (HNC) suffer from fatigue and cough and
to some degree also dyspnea [4,5,]. Smoking is a
known risk factor for both LC and HNC, thus making
COPD a common comorbidity in both diseases [6,7,].
Studies have shown a negative correlation between a
number of comorbidities, including COPD, and survi-
val of both HNC and LC [8,9,]. A recent study from
Norway comprising 174 patients newly diagnosed with
LC found that the prevalence of concomitant COPD or
emphysema was 69% [10]. Among the 212 patients
with either LC or HNC examined for inclusion in the
present study, the prevalence of COPD was 54% (69%
of those with LC and 25% with HNC) [11].
COPD is widely underdiagnosed and under-treated and
it is estimated that there are between 3- and 400.000
patients with COPD in Denmark, of which approximately
100.000 receive medical treatment [12]. Smoking cessation
is the most powerful intervention for changing disease
progression and prognosis, however, symptomatic patients
will normally require treatment with bronchodilators.
Pharmacotherapy for COPD is used to reduce symptoms,
reduce frequency and severity of exacerbations and
improve health status and exercise tolerance. The choice
of medication depends on severity of symptoms, degree of
airflow limitation and risk of exacerbations [1].
There is very limited knowledge about the possible
effects of optimizing the treatment of COPD in patients
with smoking-related cancers. The presence of COPD has
in some studies been shown to worsen the prognosis of
non-small cell lung cancer (NSCLC) but the results are not
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consistent [8,9,]. We have previously shown that patients
with LC and HNC are also underdiagnosed and/or under-
treated for COPD and that it is feasible to introduce a
pulmonary clinic in an oncological outpatient setting [11].
Regardless of the intention of the cancer treatment (cura-
tive or palliative), optimizing the management of COPD is
likely to improve patient quality of life due to the fact that
treatment with bronchodilators reduces dyspnea and fre-
quency of exacerbations [13]. Therefore, the objective of
the present study was to test the hypothesis that diagnosis
and follow-up of patients with COPD on a regular basis in
a pulmonary outpatient clinic staffed by a pulmonary
physician, established in the oncological department, can
reduce respiratory symptoms and fatigue and improve
QoL in patients with LC or HNC referred for oncological
treatment.
Material and methods
This RCT study was an investigator-initiated study.
Setting
A COPD outpatient clinic was established on 1
February 2014, at the Unit of Thoracic and Head and
Neck Oncology, Herlev University Hospital and was
staffed by a pulmonologist.
All newly diagnosed HNC and LC patients referred
to the Department of Oncology, Herlev Hospital was
screened for COPD by spirometry, and if present,
invited to participate in a randomized trial. Patients
were randomized to either continuous follow-up by
pulmonologist for 24 weeks (intervention) or manage-
ment as previously (control). All patients provided
written informed consent. The study including rando-
mization procedure, inclusion criteria, and sample size
calculation has been described in detail previously [11].
The trial was designed as a non-blinded, controlled,
randomized trial. The inclusion ran to 31 December
2014. Patients in the intervention group were offered
treatment of COPD according to Global Obstructive
Lung Disease (GOLD) guidelines 2014 [14] and were
scheduled for two control appointments at 12 and
24 weeks, respectively, where adjustment of the
COPD treatment was considered. Patients in the con-
trol group were to continue their current, if any, treat-
ment and follow-up of COPD. At first visit, the
patients filled out the following QoL-questionnaires:
European Organisation for Research and Treatment
of Cancer (EORTC) (Q30 + LC13) [15,16,] and
COPD Assessment Test (CAT) [17]. At week 13 and
week 25 CAT and EORTC questionnaires were sent to
both intervention- and control patients.
The study was approved by the local ethical com-
mittee (capital region of Denmark), H-3-2013-174.
Unfortunately, we did not register the study at trials.
gov. or another registration site.
Participants
All newly diagnosed patients with lung and head/neck
cancer referred to the Department of Oncology at
Herlev Hospital were screened for COPD with pre-
and post-bronchodilator spirometry. The only patients
not entering the screening phase of the study were
those who were planned to have now or short duration
of treatment (less than 1 month). Patients were seen at
the pulmonary clinic within the first 2 weeks after
referral. The LC patients included all primary lung
cancers, and the HNC patients included primary can-
cers in larynx, hypopharynx, oral cavity, pharynx, and
oropharynx. Patients treated with a curative as well as
palliative intent were eligible. At the first visit to the
pulmonary clinic, spirometry was performed, regard-
less of a prior COPD diagnosis. Reversibility testing
was done unless the patient had used a beta-2-agonist
the same day, in order to exclude patients with undiag-
nosed asthma. Patients with an FEV1/FVC ratio <0.70,
no significant beta-2-reversibility and no actual or pre-
vious doctor-diagnosed asthma were eligible for the
randomized trial and were invited to participate.
After inclusion, patients were randomized to either
intervention or control, and medical history and baseline
information was obtained. Based on spirometry, exacer-
bation history, MRC-grade and CAT-score, whichever
score was equal to or above the thresholds of 3 and 10,
respectively, the GOLD group was determined. The pul-
monologist assessed whether the current COPD medica-
tion was in accordance with the GOLD guidelines.
Intervention group
In the intervention group, the pulmonary physician
used the GOLD group classification to assess if there
was a need for changes in COPD medication. Choice of
drug and device was done in dialogue with the patients.
Patients were asked to demonstrate the inhalation tech-
nique using a placebo device to make sure that the
medication was taken correctly, and inspiratory capa-
city was measured with the In-Check-Dial. This was
also done with the patients’ current device if no
changes to medication were made. Patients who were
classified as GOLD group A would in most cases not
need any COPD medication. All patients were sched-
uled for a second visit to the pulmonary clinic after
12 weeks and a third visit after 24 weeks. If patients
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had only few respiratory symptoms and no medication
was prescribed, a telephone appointment rather than
physical appearance was arranged. All patients were
instructed to contact the clinic between visits if they
had questions regarding the COPD medication. The
clinic was only open once a week; hence, any acute
respiratory problems would have to be taken care of
elsewhere. At the follow-up visits, any need for changes
in the COPD medication was assessed by the physician
and discussed with the patient. Also, inhalation tech-
nique was checked again. If patients did not show up
for a scheduled visit, the physician would call the
patient and arrange for a new visit.
Control group
For the patients in the control group, no changes in the
medication were suggested, but they were encouraged
to continue any planned follow-up for COPD or make
an appointment with their general practitioner in case
of a new COPD diagnosis. All patients were informed
of the COPD diagnosis found at screening. Changes in
COPD medication after inclusion were not reported.
Follow-up
The follow-up period was 25 weeks. CAT and EORTC
questionnaires were sent to patients in both the inter-
vention group and control group at weeks 13 and 25.
The patients in the intervention group thus received
the questionnaires approximately 10 days after the
visits to the pulmonary clinic. Should the question-
naires not be returned within 1 week, the pulmonary
physician would remind the patient by phone. If the
questionnaires were not returned after 4 weeks, the
patient was considered lost to follow=up. The last
control visit was in June 2015.
Randomization
Randomization was performed 1:1 by computer using
ARRACT software and was stratified to ensure equal
distribution of sex, age, LC, and HNC between the
control group and the intervention group.
Outcomes
The primary endpoint was mean difference in change in
CAT-score over time from baseline to 13 weeks and
baseline to 25 weeks between the control group and the
intervention group. Secondary endpoints included QoL
as assessed by EORTC30 questionnaire, which is a vali-
dated QoL-questionnaire for cancer patients and the
LC13, which is a specific supplementary questionnaire
for patients with lung cancer. The LC13 questionnaire
was also used for the HNC patients since it covers symp-
toms associated with COPD. The questionnaires consist
of both single item scales and multi-item scales. The
EORTC30 is divided into global health scales, functioning
scales and symptom scales. The LC13 questionnaire only
consists of symptom scales. A higher score in global
health status and a functioning score mean better health
and higher level of functioning. A higher score in a
symptom scale means higher symptom burden. Since
the intervention was expected to relieve only respiratory
symptoms and thereby global health/functioning the fol-
lowing scales were chosen for analysis: EORTC30: global
health status, physical functioning, role functioning, fati-
gue, and dyspnea. LC13: dyspnea and coughing. A change
in functioning scales and symptom scales of 10 points is
regarded as clinically relevant [18].
CAT is an eight-question questionnaire on a VAS-
scale covering the most frequent symptoms of COPD
and validated to determine disease severity. The score
range is between 0 and 40, and a score >10 indicates a
high symptom burden. A change of 2–3 points is
regarded as clinically relevant [19,20,].
Statistical methods
Continuous variables are presented as mean with stan-
dard deviation. For categorical variables, frequency
counts and percentages are presented as summary statis-
tics for the subgroups of interest. Univariate analysis was
performed using chi-squared test for categorical data and
independent t-test for continuous variables. SPSS 21 was
used to analyze data. Power calculations showed that
either 36, 51 or 60 patients were needed in each group
to show a significant difference (MCID) in CAT-score
after the intervention of 2, 2.5 and 3 points, respectively.
This is based on a superiority design, assuming a power
(beta) of 80%, significance level (alpha) of 5%, standard
deviation (SD) 4.5 points. The SD value was chosen
arbitrarily since we had no previous data on the disper-
sion of CAT scores in a similar population.
Results
Figure 1 shows a Consort flowchart of inclusion and
follow-up. From 01.02.2014 to 31.12.2014, a total of
212 patients were assessed in the pulmonary outpatient
clinic for inclusion in the trial. Out of these 137 (65%)
had LC and 75 (35%) had HNC. One hundred and
fourteen patients with COPD were included in the trial,
LC n = 95 (83%) and HNC n = 19 (17%), and 57
patients randomized to each group.
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Of 57 patients in the intervention group, 49 (86%)
returned for the week 12 visit to the pulmonary clinic.
Two patients did not attend the week 12 visit but returned
the questionnaires. One patient came for theweek 12 visit
but died before returning questionnaires. Thus, 50 week
13 questionnaires were available for analysis. For the
scheduled week 24 visit, 43 patients attended the clinic
or had a telephone consultation. Two patients did not
attend the clinic but returned questionnaires. One had
died and three failed to return the questionnaires for
unknown reasons. A total of 41 week 25 questionnaires
were available for analysis in the intervention group. In
the control group 47 week 13 and 38 week 25 question-
naires were available for analysis.
Most of the patients who did not return the QoL-
questionnaires could not be reached and thus gave no
reason. Nine patients from the intervention group
stated that they did not feel the need for neither any
COPD medication nor visits to the clinic.
During the trial period, there was no significant
difference in mortality between the intervention
group (dead n = 7, 12.3%) and the control group
(dead = 10, 17%), p = 0.43.
Table 1 shows the baseline characteristics of the
randomized patients including performance status,
cancer type and stage, and comorbidity. Distribution
between the usual care group and the intervention
group was skewed towards a higher number of patients
with mild COPD (GOLD A) in the control group and
more women in the intervention group.
Table 2 shows mean scores in EORTC30, LC13, and
CAT at baseline. In general, there was an equal distribution
in scores between the groups. However, the usual care
group scored higher in pain than the intervention group
Figure 1. Consort flowchart of inclusion and follow up.
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(30.9 vs. 19.9). The intervention group scored higher in
dyspnea in EORTC30 (37.5 vs. 27.5); however, there was
no relevant difference in dyspnea whenmeasured in LC13.
LC13-dyspnea is a three-item scale compared to
EORTC30 – dyspnea, which is a single item scale.
Table 3 shows the differences in changes in mean
scores between baseline scores and week 13 scores and
week 25 scores, respectively, for the intervention group
(I) and the usual care group (UC). For the difference
between groups over time, a positive number means
that the intervention group scores changed in a more
positive direction than differences in scores for the
usual care group. For the symptom scales and CAT
score, a lower figure indicates improvement.
No difference between the intervention and control
group was found in CAT scores either at week 13 or
week 25. For EORTC, there were no clinically relevant or
significant differences between the groups over time in
global health status or functioning scales at either week
13 or week 25. However, in symptom scales at week 13,
there was a significant improvement in the change in
fatigue (−12.4 points, p = 0.03) in favor of the intervention.
This difference remained numerically unchanged but was
no longer significant at week 25 (−12.3, p = 0.07). At week
13 there was a clinically relevant but not significant differ-
ence in EORTC dyspnea (−11.2, p = 0.07) favoring the
intervention. However, no difference between groups was
found when the three-item scale LC13 was used (2.7,
p = 0.5), and at week 25 no differences in either
EORTC30-dyspnea (−2.7, p = 0.7) or LC13-dyspnea (0.3,
p = 1.0) were found. Multivariate analysis was also done
but no new clinically relevant or significant differences in
mean score differences emerged (data not shown).
Discussion
The overall result of our study is that this setup with
increasing focus on diagnosis and correct treatment
with inhalation medication for COPD does not attenu-
ate self-rated symptom burden or increase QoL in
patients with co-existing COPD and lung cancer. The
only significant result was EORTC Fatigue at 13 weeks
which probably is a chance finding since the same
result was not found in the CAT scores. The study
was powered for finding a difference in CAT score
and not the EORTC. Only approximately one third of
the patients were diagnosed with COPD before
Table 2. QoL-questionnaires at baseline. Figures are presented
as mean (SD).
EORTC 30
Scale/item Intervention Control
Global health status n: 55/57 57.4 (23.11) 60.2 (26.4)
Functional scales
Physical functioning n: 56/57 75.7 (19.5) 76.0 (24.9)
Role functioning n: 56/57 63.4 (26.1) 69.6 (34.2)
Emotional functioning n: 56/57 78.8 (19.8) 74.0 (22.5)
Cognitive functioning n: 56/57 86.6 (16.9) 80.7 (24.2)
Social functioning n: 55/57 82.2 (16.7) 82.2 (22.5)
Symptom scales/items
Fatigue n: 56/56 42.9 (25.7) 35.6 (29.5)
Nausea and vomiting n: 56/56 13.1 (19.8) 9.5 (16.8)
Pain n: 56/57 19.9 (23.6) 30.7 (33.2)
Dyspnea n: 56/57 37.5 (29.9) 27.5 (29.0)
Insomnia n: 56/57 19.9 (23.6) 30.7 (33.2)
Appetite loss n: 55/57 35.8 (32.6) 28.7 (32.4)
Constipation n: 56/56 17.3 (26.9) 16.7 (29.1)
Diarrhea n: 55/55 9.7 (20.0) 12.12 (25.1)
Financial difficulties n: 55/57 7.9 (18.1) 7.6 (17.8)
EORTC/LC13
Dyspnea n: 54/55 26.9 (23.0) 28.5 (21.2)
Cough n: 54/57 41.4 (27.4) 31.6 (27.8)
Haemoptysis n: 55/57 3.0 (11.6) 3.5 (12.1)
Sore mouth n: 54/57 14.2 (25.6) 7.0 (20.6)
Dysphagia n: 55/57 15.2 (30.0) 14.6 (26.7)
Peripheral neuropathy n: 54/57 5.6 (15.5) 8.8 (21.4)
Alopecia n: 55/57 3.0 (11.6) 4.7 (17.2)
Pain in chest n: 55/57 13.9 (21.9) 20.5 (28.7)
Pain in arm or shoulders n: 55/56 15.8 (24.7) 16.7 (29.8)
Pain in other parts n: 54/54 24.1 (32.4) 24.1 (32.0)
CAT score 13.1(6.8) 12.7 (7.8)
Table 1. Baseline characteristics of the patients. Figures are
presented as mean (SD) or numbers (%).
Characteristics
Intervention
group
n: 57
Control
group
n: 57
Age (years) 67.6 (8.3) 67.2 (8.1)
Sex (female) 24 (42.1%) 18 (31.6%)
BMI 23.5 (3.8) 23.7 (4.8)
Performance status
0 25 (43.9%) 25 (43.9%)
1 26 (45.6%) 25 (43.9%)
2 6 (10.5%) 7 (12,3%)
Lung cancer 48 (84%) 47 (82.5%)
NSCLC 44 (91.7%) 42 (89.4%)
NSCLC stage 1 + 2 4 (8.4%) 5 (10.7%)
NSCLC stage 3 + 4 40 (83,3%) 37 (78,7%)
SCLC 4 (8,3%) 5 (10.6%)
SCLC stage, Limited 3 (6.3%) 0
SCLC stage, Extensive 1 (2.1%) 5 (10.6%)
Head and neck cancer 9 (15.8%) 10 (17.5%)
Stage 1 + 2 3 (33.3%) 3 (30%)
Stage 3 + 4 6 (66.7%) 7 (70%)
Comorbidities
Ischaemic heart disease/heart failure 7 (12.3%) 6 (10.5%)
Depression/anxiety 2 (3.5%) 2 (3.5%)
Osteoporosis 7 (12,3%) 6 (10.5%)
Cerebrovascular disease 8 (14.0%) 5 (8.8%)
Diabetes 8 (14.0%) 5 (8.8%)
Spirometry
FEV1 (l) 1.75 (0.59) 1.86 (0,69)
FEV1 of expected (%) 65.2 (16.0) 64.6 (19,5)
FVC (l) 2.93 (0.89) 3.12 (10,3)
FEV1/FVC 0.60 (0.09) 0,59 (0,09)
COPD
GOLD A 17 (29.8%) 26 (45.6%)
GOLD B 22(38.6%) 15 (26.3%)
GOLD C 3 (5.3%) 3 (5.3%)
GOLD D 15 (26.3%) 13 (22.8%)
Diagnosed before inclusion 20 (35.1%) 17 (29.8)
Correct treatment before inclusion 24 (42.1%) 31 (54.4%)
Smoking status
Current smoker 16 (28.1%) 11 (19.3%)
Pack years 42.2 (22.3) 42.7 (21.0)
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inclusion and of these only around 50% received the
correct inhalation medication according to GOLD.
Unfortunately, the distribution of patients in GOLD
A-D was skewed towards more patients in the control
group being in group A compared to the intervention
group (45% vs. 30%). This would, however, have made
a positive finding likelier.
A limitation of this study is that the statistical power
was limited due to small sample size. The SD chosen
for the power calculation (4.5) is slightly lower than
found in intervention studies of COPD [21]. With a
larger study, the ability to detect significant differences
would increase. There is also a risk that an underpow-
ered study may not detect real differences due to
change variation. However, the trend in our observa-
tions does not indicate an effect of the intervention.
For example, the CAT score actually worsened in the
intervention group, while is slightly improved in the
control group (CAT scores +0.8 and −0.4, respectively).
Unexpectedly the baseline CAT score was only
approximately 13 in both groups, which also makes it
more difficult to detect improvements from an inter-
vention. In future studies, careful consideration of
study size (e.g. including more study sites), type of
intervention and outcome (e.g. a composite QoL end-
point) is warranted.
It is highly possible that the follow-up period of
25 weeks was not long enough for detecting a true
difference. The relatively large loss to follow-up is
also of concern, since this can possibly introduce an
information bias, meaning that those who are most ill
(or most well) are also most likely not to return the
schedules or show up for an appointment. The reasons
for this loss to follow-up could possibly be skewed
between the arms. Another likely explanation for the
negative result could be that both the symptomatology
and the focus of attention in the current context are
driven by the cancer and not the COPD. A recent study
from Spain, very similar to ours but retrospective,
found a 29% prevalence of COPD in their cohort of
LC patients and also that 60% were undiagnosed prior
to the LC diagnosis [22]. Not unexpectedly, those with
a known COPD diagnosis had more severe airway
obstruction and COPD-related symptoms, whereas
the LC was more progressed in patients with newly
diagnosed COPD. Nevertheless, even if this is the pri-
mary explanation for this negative result, the treatment
of COPD has since 2014 and to date increased the
focus on dual bronchodilation. This continuous devel-
opment in treatment of COPD might have influenced
the results. We do not have data on how many of the
patients were treated with only one bronchodilator
and/or inhaled corticosteroids (ICS) in the two groups,Ta
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respectively. A very recent observational Swedish study
of risk factors for LC in a large cohort of patients with
COPD found that a diagnosis of concomitant asthma
and prescription of ICS was independent predictors of
a decreased risk of developing LC [23]. The study was,
however, limited by no information of pack years of
smoking and no recent spirometry for classifying the
severity of COPD. We do not have any data on adher-
ence to prescribed medication for COPD in the present
study. This is a key issue in the treatment of COPD,
where adherence is known to be low in general [24]. It
is possible that patients in the control group, who
underwent a spirometry and were either diagnosed
with COPD or reminded of this disease had a medical
follow-up outside this randomized setting. In this case,
it would dilute any effect of our intervention.
Moreover, patients in the control group could possibly
already be treated optimally by their general
practitioner.
Another limitation is that the pulmonary outpatient
clinic did not offer any form of pulmonary rehabilita-
tion, which may be a central reason for the negative
result. Pulmonary rehabilitation has been shown to be
the most effective therapeutic strategy to improve
symptoms and health status [25]. Furthermore, we do
not have data on medication adherence which also may
influence the negative result. At the start of an onco-
logical treatment at lot of new information is given,
that probably weakens the patients’ focus on new inha-
lers. Finally, we did not have any smoking cessation
intervention as part of our study and the possible
continued tobacco smoking may cause continued
symptoms.
The massive symptom burden of lung cancer alone
makes it difficult to improve QoL and optimizing
medication for concomitant COPD, i.e, for dyspnea
relief may rather have to be a part of a palliative
approach. Specialized palliative care has been shown
to improve QoL for patients with lung cancer [26],
hence focusing almost solely on inhalation medication
might not be enough to improve self-rated QoL or
symptom burden for patients with both COPD and
lung cancer. With this in mind, we still believe that it
is not worthless to diagnose and address COPD in
patients with newly diagnosed lung cancer.
Conclusion
In conclusion, the present study indicates that inter-
vention focusing almost exclusively on optimizing
inhaled medication for COPD patients with co-existent
lung cancer does not improve symptom control and
QoL as assessed by the CAT-questionnaire. We
conclude that further, larger studies are needed to
improve care of patients with COPD and lung cancer.
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